Eleven Biotherapeutics Reports Fiscal First Quarter 2014 Financial Results

Eleven Biotherapeutics Reports Fiscal First Quarter 2014 Financial Results

May 15, 2014

- Enrollment Complete in EBI-005 Phase 2 Allergic Conjunctivitis Study -

BG Medicine Reports First Quarter 2014 Financial Results

BG Medicine Reports First Quarter 2014 Financial Results

May 14, 2014

 BG Medicine Reports First Quarter 2014 Financial Results

Net Loss Reduced by 60% and Operating Cash Burn Cut by 44% From First Quarter 2013

Continued Progress Made Toward Delivering on Critical Catalysts for Growth

WALTHAM, Mass., May 14, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3(R) Test, today reported financial results for the first quarter ended March 31, 2014.

Agios Pharmaceuticals Appoints Chris Bowden, M.D., as Chief Medical Officer

Agios Pharmaceuticals Appoints Chris Bowden, M.D., as Chief Medical Officer

May 14, 2014

Appointment Reflects the Strength of Agios’ Clinical Development Pipeline

Concert Pharmaceuticals Reports First Quarter 2014 Financial Results

Concert Pharmaceuticals Reports First Quarter 2014 Financial Results

May 14, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2014.

Avedro Welcomes Robert J. Palmisano to its Board of Directors

Avedro Welcomes Robert J. Palmisano to its Board of Directors

May 14, 2014

Seasoned Veteran in Value Creation for Ophthalmic Medical Device Companies

Receptos Reports First Quarter 2014 Financial Results

Receptos Reports First Quarter 2014 Financial Results

May 12, 2014

- Top-line results of Phase 2 trial of RPC1063 in relapsing multiple sclerosis expected in mid-2014 -

- Phase 3 trial of RPC1063 in relapsing multiple sclerosis enrolling patients globally -

- Results of Phase 2 trial of RPC1063 in ulcerative colitis expected in Q4 2014 - 

SAN DIEGO, May 12, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. today provided development program updates and announced financial results for the first quarter ended March 31, 2014.

BIND Therapeutics Reports First Quarter 2014 Financial Results and Updates BIND-014 Clinical Development Plan

BIND Therapeutics Reports First Quarter 2014 Financial Results and Updates BIND-014 Clinical Development Plan

May 8, 2014

- BIND to expand trial program to evaluate BIND-014 in NSCLC with KRAS mutations -

Agios Pharmaceuticals Reports First Quarter 2014 Financial Results

Agios Pharmaceuticals Reports First Quarter 2014 Financial Results

May 8, 2014

AG-221 Showed Promising Clinical Activity in AML; Additional Data to be Presented at EHA

Three First-in-Class Compounds now in Clinical Development

CAMBRIDGE, Mass., May 08, 2014 (BUSINESS WIRE) -- Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), today reported business highlights and financial results for the first quarter ended March 31, 2014.

Eleven Biotherapeutics Presents Data on Novel Protein Therapeutics for Treatment of Front and Back of Eye Diseases at ARVO 2014 Annual Meeting

Eleven Biotherapeutics Presents Data on Novel Protein Therapeutics for Treatment of Front and Back of Eye Diseases at ARVO 2014 Annual Meeting

May 6, 2014

 Clinical Data on EBI-005 Demonstrated Improvements in Signs and Symptoms in Patients with Dry Eye Disease through IL-1 Inhibition

Preclinical Data on EBI-029 Demonstrated Inhibition of IL-6 as a Validated Target for Treating Diabetic Macular Edema

Eleven Biotherapeutics Appoints Gary Sternberg, M.D., M.B.A., as Executive Vice President Corporate and Business Development

Eleven Biotherapeutics Appoints Gary Sternberg, M.D., M.B.A., as Executive Vice President Corporate and Business Development

May 5, 2014

 Industry veteran and ophthalmologist brings product licensing and business development expertise